Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 66.50
Bid: 65.00
Ask: 68.00
Change: 0.00 (0.00%)
Spread: 3.00 (4.615%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 66.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Steve Curd appointed as CEO of Wanda

9 Sep 2015 13:00

RNS Number : 5652Y
NetScientific PLC
09 September 2015
 

 

NetScientific plc

 

 

NetScientific announces the key appointment of Steve Curd as CEO of Wanda, Inc.

 

London, UK - 9 September 2015 - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces the appointment of Steve Curd as CEO of its portfolio company, Wanda, and head of the Group's Digital Health franchise, of which Wanda is the key asset.

Wanda helps healthcare providers improve outpatient care while reducing the costs associated with managing chronic diseases. The company provides a cloud based patient management solution combining comprehensive data-mining and advanced analytics to give clinicians a complete view of their outpatients' current and trending health. Its first medical product is Wanda™ CHF, a clinical decision support system for remotely managing patients with Congestive Heart Failure to help prevent hospital readmissions.

Steve Curd will join the Group on 14th September 2015 to oversee the growth and delivery of its digital health portfolio. He has more than 20 years' experience in driving growth for digital healthcare, commercialising products and delivering exits. Steve has helped secure 15 M&A transactions and numerous successful exits for Digital Health companies. Most recently, Steve was the COO of NantHealth, a healthcare company converging biomolecular medicine and bioinformatics with technology services, where he was responsible for advancing its product portfolio, driving improvements in efficiency and improving client satisfaction. Prior to that, he was CEO at CareInSync, an innovative mobile care coordination platform start-up where he grew the team, refined the business model and improved sales. Other notable positions include CIO at UnitedHealth Group, COO at WebMD, and CEO at VantageMed.

Francois Martelet, Group CEO of NetScientific, commented: "I am delighted to welcome a leader of Steve's calibre to the Group to drive the commercialisation programme for Wanda, our game-changing clinical decision support system. Steve is highly regarded in this area and will play a key role in accelerating the growth of our digital health portfolio, one of our three areas of strategic focus together with diagnostics and therapeutics."

Steve Curd commented: "Wanda represents the next generation of digital health solutions for patient care and I'm excited about the opportunity to drive its commercialisation phase. I look forward to working with NetScientific's diverse mix of digital health companies as its technologies have a real potential to become first or best in class technologies that could improve the lives of millions of people living with chronic diseases."

- Ends -

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website at www.netscientific.net. 

 

About Wanda Health

Wanda Health (Wanda, Inc.) is developing cloud-based analytics, as part of a total patient management solution, in partnership with other healthcare providers. The core analytics engine is based on 12 years of research at the Wireless Health Institute at UCLA. Wanda Health has completed development of a predictive analytics engine for use in remotely monitoring patients with Congestive Heart Failure, the leading cause of hospital re-admissions in USA.

 

Contact Details

NetScientific

Peter Thoms, CFO

Tel: +44 (0)77 2055 5752

Investec

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSLFFUFISELU
Date   Source Headline
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
27th Jun 20228:30 amRNSHolding(s) in Company
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101
15th Feb 20222:32 pmRNSPDS Clinical Trial with Mayo Clinic
2nd Feb 20223:00 pmRNSPDS Phase 2 Trial Update
28th Jan 20228:45 amRNSPDS Announces Preclinical Data for PDS0202 Vaccine
18th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20222:20 pmRNSPDS Granted Novel HPV16 Immunotherapy Patent
10th Jan 20227:00 amRNSProAxsis CEO End of Year Update
29th Dec 20218:47 amRNSIssue of Equity
21st Dec 20211:59 pmRNSTR-1: Form for notification of major holdings
21st Dec 20217:00 amRNSQ-Bot Investment and Share Acquisition
20th Dec 20217:00 amRNSAcquisition of majority stake in Cetromed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.